Biomarkers and Prognosis After Myocardial Infarction: Towards Precision Cardiology

Clicks: 2
ID: 313977
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #63 of 73 articles by views in european heart journal - quality of care and clinical outcomes

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Cardiovascular diseases remain the leading cause of mortality worldwide, underscoring the urgent need for improved strategies to reduce their global burden. Despite significant advances in the acute management of myocardial infarction (MI) -notably in reducing short-term mortality and extending patient survival- key gaps persist in our understanding of post-infarction pathophysiology and risk stratification. In particular, predicting long-term outcomes and adverse cardiovascular events following MI continues to be a major clinical challenge. This review provides an overview of emerging biomarkers supported by current scientific evidence that show promise in enhancing prognostic assessment after MI. While cardiac troponins and natriuretic peptides remain the standard for diagnosis and initial risk evaluation, novel biomarkers such as galectin-3, lipoprotein(a), receptor for advanced glycation end-products and non-coding RNAs have been associated with increased risk of mortality and major adverse cardiovascular events. A deeper exploration of their biological roles and related signalling pathways may contribute to the identification of new therapeutic targets. In parallel, recent advances in omics technologies, imaging modalities and digital monitoring are enabling more refined phenotypic characterization of post-MI patients, paving the way for personalized management strategies. Altogether, these developments offer a path toward improved prognostication, targeted therapies, and ultimately better clinical outcomes for individuals recovering from MI.
Reference Key
openalex_W7161606310 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Simón Rodríguez-Moar, Carmen Neiro-Rey, David Garcia-Molinero, José María García‐Acuña, Pedro Rigueiro‐Veloso, D Iglesias-Alvarez, Brais Díaz‐Fernández, Miguel Souto-Bayarri, José Ramón González‐Juanatey, Ezequiel Álvarez, Rosa María Agra-Bermejo
Journal european heart journal - quality of care and clinical outcomes
Year 2026
DOI
10.1093/ehjqcco/qcag086
URL
https://doi.org/10.1093/ehjqcco/qcag086
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.